CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation by unknown
RESEARCH ARTICLE Open Access
CTLA4 is expressed on mature dendritic cells
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Abstract
Background: Dendritic cells (DCs) initiate immune responses through their direct interaction with effector cells.
However, the mechanism by which DC activity is regulated is not well defined. Previous studies have shown that
CTLA4 on T cells regulates DCs function by “cross-talk”. We investigated whether there is an intrinsic regulatory
mechanism in DCs, with CTLA4 as a candidate regulator.
Results: We confirmed via RT-PCR and flow cytometry the natural expression of CTLA4 on mature DCs derived
from human monocytes. Approximately 8% CD1a-positive cells express CTLA4 both on surface and intracellular,
whereas 10% CD1a-negative cells express CTLA4 intracellularly, but little expression was observed on the cell
surface. The cross-linking of CTLA4 inhibits DCs maturation and antigen presentation in vitro, but does not inhibit
endocytosis.
Conclusions: CTLA4 is expressed by DCs and plays an inhibitory role. CTLA4-expressing DCs may represent a
group of regulatory DCs. Because of its wide distribution on different cell types, CTLA4 may play a general role in
regulating immune responses.
Background
Dendritic cells (DCs) are sparsely distributed in tissues
and the circulation, but they are nevertheless important.
They function as professional antigen-presenting cells
(APCs) in antigen capture, processing, and presentation
to CD4+ and CD8+ T cells [1]. DCs can be produced in
vitro by a number of procedures, starting from CD34+
hemopoietic progenitor cells (from peripheral blood or
bone marrow) cultured with tumor necrosis factor a
(TNFa) and granulocyte macrophage-colony-stimulating
factor (GM-CSF), or from human blood monocytes cul-
tured with GM-CSF, interleukin 4 (IL-4), or IL-13.
Immature DCs (iDCs), which have a high capacity for
antigen uptake and processing, but a low capacity to sti-
mulate T-cell proliferation, can be further differentiated
in vitro to mature DCs (mDCs), which have a high capa-
city for antigen presentation, by treatment with TNFa,
lipopolysaccharide (LPS), IL-1, or CD40L. Many costi-
mulatory factors are expressed by DCs and play impor-
tant roles in the communication between DCs and
immunocompetent cells [2,3]. The functions of DCs are
also regulated by the mutual cross-talk between costi-
mulatory molecules [3]. The additional expression of
activating costimulatory molecules that favor the inter-
action between DCs and T cells further enhances the
ability of DCs to generate antitumor immune responses.
Activating costimulatory molecules that have been upre-
gulated on DCs by genetic engineering include the
CD40 ligand (CD40L) [4-6], CD70 [7], 4-1BBL [8], the
OX40 ligand (OX40L) [9], and the receptor activator of
NF-B (RANK)/RANK ligand (RANKL) [10].
CTLA4 (CD152) is an inhibitory costimulatory mole-
cule. The expression and function of CTLA4 in T cells
have been well studied and the effect of CTLA4 on DCs
has also been studied. CTLA4 acts as a ligand to induce
interferon g (IFNg) production by DCs and to prevent
T-cell responses via a mechanism that involves trypto-
phan catabolism [11]. CTLA4-immunoglobulin (Ig) may
inhibit DC function through the B7 receptor on DCs,
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which indicates cross-talking between costimulatory
molecules. A dendritic cell line genetically modified to
express CTLA4-Ig suppressed the alloimmune response
and prolonged the survival of islet allografts in an
allospecific manner [12]. APCs transfected with a gene
construct encoding a modified CTLA4 molecule
(CTLA4-KDEL) failed to express CD80/86 on their sur-
faces and were unable to stimulate allogeneic or pep-
tide-specific T-cell responses. The cells also induced
antigen-specific anergy of the responding T cells, with
no up-regulated expression of the indoleamine 2,3-diox-
ygenase enzyme [13]. There is evidence that DCs play a
central role in immune therapy with CTLA4-Ig insofar
as Ko et al. [14] demonstrated that when CD11c+ DCs
from collagen-induced arthritis (CIA) mice were treated
with CTLA4-Ig and adoptively transferred into mice
with CIA, no arthritis developed in association with an
increase of the CD4+CD25+Foxp3+ Treg population.
However, in CTLA4-Ig-untreated DC-transferred CIA
mice, arthritis developed and then progressed rapidly.
CTLA4 is reported to be expressed on T and B lym-
phocytes [15,16], monocytes [17], placental fibroblasts
[18], human muscle cells [19], CD34+ stem cells, granu-
locytes [20,21], mouse embryonic stem cells and embry-
oid bodies [22]. CTLA4 is also expressed in leukemia
cells [23] and many cell lines and tumor cells [24]. We
hypothesized that CTLA4 is also induced on DCs. The
aim of the present study was to investigate the natural
presence of CTLA4 on human DCs and the effects of
CTLA4 on human DCs differentiation and maturation.
Results
Characteristics of DCs
After five days in culture, the cells showed the charac-
teristics typical of iDCs: aggregated cells with extended
protrusions visible under microscopy, CD19, CD14,
CD3 negative, and CD80, CD86, and HLA-DR-positive
phenotype, as demonstrated by FACS (data not shown).
After challenge with TNFa plus LPS, the cells were
more heterogeneous: some loosely adhered to the plastic
surface and others were more buoyant, with long den-
drites. The cells were CD83 positive on FACS analysis.
CD40, HLA-DR, CD80, and CD86 were strongly
expressed (data not shown).
Cellular expression of CTLA4
As expected, CTLA4 was expressed intracellularly and
on the surfaces of mDCs but not on iDCs, as deter-
mined by FACS analysis (Figure 1). A very interesting
finding is that both CD1a positive and negative mDCs
express CTLA4, but in a different manner. On the sur-
face, about 7.51 ± 1.45% (range 5.1-9.5%) of CD1a-
Figure 1 CTLA4 is naturally expressed by mDCs. A. Flow-cytometric analysis of DCs expressing CTLA4. iDCs and mDCs were stained on their
surfaces or intracellularly with the designated antibodies.
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positive mDCs from 10 healthy adults expressed CTLA4
compared to 3 ± 1.38%(1.98-3.9%) CD1a-negative
mDCs. Intracellularly, 10.64 ± 2.17% (7.3-13.8%) CD1a-
positive mDCS expressed CTLA4 compared to 10.13 ±
3.04%(7.8-13.31%) CD1a-negative mDCs. To verify the
specificity of anti-CTLA4 antibody binding, unconju-
gated CTLA4 antibody was used to block staining with
anti-CTLA4-PE antibody. This staining was blocked by
the anti-CTLA4 antibody but not by isotype-matched
anti-CD3 antibody. CTLA4 mRNA was undetectable by
RT-PCR in iDCs. mDCs induced by LPS plus TNFa
expressed CTLA4 mRNA (Figure 2) and this was con-
firmed by sequencing the PCR products.
Cross-linking of CTLA4 inhibits DC maturation
iDCs were transferred to anti-CTLA4-antibody-coated
plates and LPS and TNFa were added. After two days in
culture, the cells were harvested for FACS analysis. FACS
data revealed that CD83 expression was inhibited in a
dose dependent manner by treatment with anti-CTLA4
antibody (Figure 3a). A more than 70% reduction of
CD83 means fluorescence intensity (MFI) was achieved
after the cells were cultured in plates coated with 1 μg/
mL anti-CTLA4 antibody. Because CD83 is commonly
used as a marker for mature DCs, the reduced expression
of CD83 on DCs suggests the inhibition of DCs matura-
tion. At the same time, CD80, CD86, HLA-DR expres-
sion was analyzed. Unexpectedly, there is no significantly
effect of anti-CTLA4 antibodies on their expressions.
Unlike the CTLA4-KDEL gene transfer which can block
CD80 and CD86 expression [13], the crossing-linking of
CTLA4 does not alter the basic feature of DC.
Cross-linking of CTLA4 inhibits MLR and Ag presentation
mDC are potent stimulators of allogeneic T cells. We
investigated the possibility that cross-linking of CTLA4
affects the MLR response. Various numbers of stimulators
were used and proliferation was determined by [3H]-thy-
midine incorporation. The treated cells showed an
impaired capacity to induce MLR (Figure 3b). However,
no effect was seen in iDCs treated with anti-CTLA4 anti-
body (data not shown). Because mDCs are professional
APCs, we investigated Ag presentation by mDCs. As
CTLA4 is strongly expressed on activated T cells, we trea-
ted mDCs separately with either anti-CTLA4 monoclonal
antibody or control antibody. As expected, antigen presen-
tation was reduced when mDCs were cultured in anti-
CTLA4-antibody-coated plates, which was demonstrated
by the reduced proliferative response of specific autolo-
gous T-cell lines in the presence of PPD (Figure 3c). The
same tendency was observed when tetanus toxoid (50 μg/
mL) was used as the challenge (data not shown).
CTLA4 does not inhibit endocytosis in iDCs
The culture of iDCs in anti-CTLA4-antibody-coated
plates did not influence their endocytosis (Figure 4).
This result is consistent with the expression analysis
that showed that CTLA4 was not detectable in iDCs.
Discussion
Here, we have confirmed that CTLA4 is expressed natu-
rally on mDCs but is undetectable on iDCs. During the
revision of this paper, Shankar [25] reported that human
PBMC-derived DCs express CTLA4 strongly on their
surfaces in response to CH3·SAM (self-assembled mono-
layers) contact (a kind of biomaterial) when compared
with all other treatments. This result is consistent with
our data.
CD1a was widely used as human DCs marker several
years ago. In recent years, CD1a negative DCs have
been identified [26,27]. It is clear now that DCs are a
heterogeneous population with peculiar phenotypic and
functional features, regardless of whether they are gen-
erated from human monocytes or CD34+-hematopoietic
progenitors [28]. However, there is no full picture of
DCs subgroups to date. Surface expression of CTLA4
was favored on CD1a-positive mDCs whereas intracellu-
lar expression occurred not only in CD1a-positive, but
also in CD1a-negative mDCs. The percentage of
CTLA4-positive staining was slightly higher for intracel-
lular than for surface staining of CD1a-positive cells. As
intracellular staining covers both the surface and the
cytoplasm, surface positive mDCs may represent a
group of regulatory mDCs, which may be the same as
the situation for T cells. About 10% CD1a-negative
mDCs expressed CTLA4 intracellularly, but not on the
cell surface. This group of cells may represent a
Figure 2 CTLA4 mRNA was detected in mature DCs but not
immature DCs, as determined by RT-PCR. The cells were purified
by sorting with flow cytometry. iDC: immature DCs; mDC: mature
DCs; M: molecular ladder. A representative experiment is shown.
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particular population with unknown function. Further
studies to determine if there are regulatory DCs would
be very interesting. It is also important to define the
characters of CTLA4-positive CD1a positive or negative
mDCs via phenotype and function analyses.
The precise function of CTLA4 in non-T cells is lar-
gely unknown. It is reasonable to infer that CTLA4
plays an inhibitory role via different mechanisms in dif-
ferent cell types, but some mechanisms may also be
shared by different cell types. According to the limited
data available, CTLA4 plays a negative role in the cell
activity of non-T cells. A balance between stimulatory
and inhibitory signals is required for effective immune
responses and the B7 and CD28 superfamilies are major
regulators of this critical balance, because key positive
and negative second signals are provided by these path-
ways. The function of CTLA4 in T cells has recently
been reviewed [29] and summarized as seven activities:
1. increases the threshold for cytokine production and
proliferation; 2. inhibits cell-cycle progression and tran-
scription factors NF-B, NF-AT, and AP-1; 3. induces
indoleamine 2,3-dioxygenase release by dendritic cells;
Figure 3 Cross-linking of CTLA4 inhibits DC maturation (A), the mixed lymphocyte response (B), and antigen presentation (C). *: P <
0.05 anti-CTLA4 antibody vs control antibody. A representative of three experiments is shown. A: Relative mean fluorescence intensity (MFI;
MFItreated - MFIiDC) of CD83 was measured. DCs were seeded in wells coated with anti-CTLA4 antibody or isotope control antibody at the
indicated concentrations, and mature DCs were used as the positive control. B: Mature DCs after challenge in plates coated with anti-CTLA4 or
control antibody were used as the stimulators and allogeneic PBMC-derived T lymphocytes as the responders. DCs and T cells were mixed in
different ratios with a constant number of T cells (2 × 105 cells/well). T-cell proliferation was measured in triplicate by the incorporation of [3H]-
thymidine and is expressed as cpm. C: Effect of CTLA4 cross-linking on the presentation of PPD to specific T-cell lines. After PPD pulsing, DCs
were further cultured with maturation-inducing stimuli in plates coated with anti-CTLA4 antibody or control antibody at the indicated
concentrations. The cells were then washed extensively and mixed with PPD-specific autologous T-cell lines. Proliferation was assessed as [3H]-
thymidine uptake.
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4. modulates the composition and cell-surface expres-
sion of lipid rafts; 5. upregulates LFA1-mediated adhe-
sion via the activation of RAP1; 6. increases cell motility
and reverses the T-cell-receptor-induced stop signal;
and 7. reduces T-cell-APC contact time. Moreover.
CTLA4 affects T cells motility [30,31]. Another function
of CTLA4 is in the protection of cells from apoptosis.
Hoff et al. demonstrated that the protection of cells
from apoptosis by CTLA4 is dependent on the suppres-
sion of the FAS/FASL system and is mediated by the
PI3K-dependent activation of the kinase AKT, leading
to the inhibition of the proapoptotic molecule BAD
[32]. All these functions may be used as references in
determining the CTLA4 function in DCs. Although the
present data and other studies [12] suggest CTLA4
plays an inhibitory role in the main functions of DCs,
the mechanisms involved remain to be identified, espe-
cially the signal pathway in DCs.
Two types of bidirectional cross-talk between different
cells play important role: 1. reverse signaling such as
CD47 and signal-regulatory protein-a (SIRP-a) [33], CD40
and CD154 [34], and CD200 and CD200R [35]. 2. coex-
pression of some ligands and their receptors on the same
cells. We have observed that T cells express not only
CD28 and CTLA4, but also CD80 and CD86 when acti-
vated [36]. It has been reported that activated B cells not
only express CD80 and CD86, but also CTLA4 [15].
CTLA4, acting as ligand, could regulate DC function
[11-14]. The finding of natural expression of CTLA4 by
DCs supports bidirectional communication as a possible
mechanism. The bidirectional signaling mediated by pairs
of membrane-anchored coreceptor molecules is likely to
be an important feature of the DC-T-cell interaction.
DCs are powerful APCs, and can present antigens to
CD4+ and CD8+ T cells while delivering the costimula-
tory signals necessary for T-cell activation. CTLA4
expressed on DCs could finely regulate the functions of
DCs. The results of our experiments, in which we used
an anti-CTLA4 antibody to cross-link the surface
CTLA4 molecules on DCs, suggest that the function of
CTLA4 on DCs is to down-regulate their maturation
and antigen presentation. The results of our functional
studies are also supported by the transfection of a gene
construct [13] that encodes a modified CTLA4 molecule
(CTLA4-KDEL). Although less than 10% of DCs
expressed CTLA4, the power of CTLA4 is still great.
Beside direct contact, the mechanism for this potent
inhibitory role may involve cytokine secretion by
CTLA4-expressing DCs. We propose that CTLA4-
expressing DCs may represent a group of regulatory
DCs that can regulate DCs function. Future work will
involve characterization of phenotypes and functions of
CTLA4-expressing DCs.
Conclusions: DCs are specialized regulators of innate
and adaptive immunity. Because CTLA4 is expressed
not only on T cells but also on various other cell types,
we believe that CTLA4 plays a global role in the finely
tuned regulation of cell activity in vivo. CTLA4-expres-
sing DCs may represent a group of regulatory DCs. Our
demonstration of the natural, functional expression of
CTLA4 on DCs increases the evidence of general role of
CTLA4 and further confirms the importance of CTLA4
in the immune system.
Methods
Cytokines and reagents
Recombinant human GM-CSF (1.1 × 104 U/μg), recom-
binant human IL2 (2 × 106 U/mg), and recombinant
human TNFa (specific activity >2 × 107 U/mg) were
obtained from PeproTech (London, UK). Recombinant
human IL4 was obtained from R&D Systems (R&D Sys-
tems, Minneapolis, MN). LPS was from Escherichia coli
(055:B5; Sigma, St Louis, MO). Mycobacterium tubercu-
losis purified protein derivative (PPD), manufactured at
the Statens Serum Institute, Denmark, was supplied by
SBL Vaccin AB, Stockholm, Sweden. Purified anti-
human CTLA4 (CTLA4) and mouse IgG2a  isotope
controls or anti-human CD3(IgG2a) were purchased
from Pharmingen (San Diego, CA, USA).
DCs culture
Highly enriched monocytes (>80% CD14+) were
obtained from buffy coats on Ficoll gradients and puri-
fied by peripheral blood mononuclear cell (PBMC)
adherence. Nonadherent cells were depleted by washing
three times with phosphate-buffered saline (PBS). The
adherent cells were recovered; CD2+ and CD19+ cells
Figure 4 The culture of immature DCs in wells coated with
anti-CTLA4 antibody did not affect their endocytic activity.
Endocytosis was evaluated as the uptake of FITC-DX at the
indicated times, which was measured by FACS. The data for one
experiment are shown, and are representative of three independent
experiments.
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were depleted with a negative selection kit (Dynabeads
M450; Dynal, Oslo, Norway). This procedure resulted in
a 97% pure CD14+ monocytes preparation. Monocytes
were cultured for seven days at 1 × 106/mL in 24-well
multi-well tissue-culture plates (Falcon, Becton Dickin-
son, Stockholm, Sweden) in RPMI 1640 medium (Invi-
trogen AB, Stockholm, Sweden,) in 10% fetal calf serum
(FCS) supplemented with 60 ng/mL GM-CSF and 50
ng/mL IL4. The medium was changed every second day
by removing half the medium and adding freshly made
medium supplemented with full concentrations of cyto-
kines. To obtain mDCs, 100 ng/mL LPS and 10 ng/mL
TNFa were added.
RT-PCR amplification and sequencing of human CTLA4
The CD1a-positive cells were sorted on a MoFlo high-
speed cell sorter (Dako, Glostrup, Denmark) equipped
with a Coherent Innova 70C laser tuned to 488 nm.
Fluorescein isothiocyanate (FITC) fluorescence emission
was detected with a 530/40 optical filter. Rhodamine
phycoerythrin (RPE) fluorescence emission was detected
with a 580/30 optical filter. Mature DCs were sorted
based on gates set on forward scatter versus side scatter
and CD83-PE expression. iDCs were sorted based on
gates set on forward versus side scatter and CD1a FITC
expression. Doublets were discriminated and excluded
using a gate set on forward scatter versus pulse width.
No T cells were identified by fluorescence-activated cell
sorting (FACS) analysis. Purified DCs (2 × 106) were
lysed in 500 μL of a total RNA isolation reagent (Ultra-
spec-II RNA, Biotech, Stockholm, Sweden). cDNA was
prepared with the RNA PCR Core kit (PerkinElmer,
Foster City, CA). The primers used to amplify the entire
coding sequence of CTLA4 were 5’-ATGGGCCACA-
CACGGAGGCA-3’ and 5’-TACACTTTCCCTTCT-
CAATCTCTCAT-3’. The PCR conditions were as
follows: 94°C for 5 min, 35 cycles of 94°C for 1 min,
56°C for 1 min, and 72°C for 1.5 min, followed by a final
extension at 72°C for 5 min. The amplified fragments
were separated and identified on a 2% GTG agarose gel.
The fragments were subcloned into a TA cloning vector
(PCRII, Invitrogen, Leek, Netherlands). Sequencing was
performed with the ABI PRISM BigDye Terminator
Cycle Ready Reaction Kit (PerkinElmer, Wellesley, MA).
FACS analysis
Cell staining was performed with CD1a-FITC (clone
WM35 from Nordic BioSite AB), CD3-PerCP, CD14-
FITC, CD19-FITC, CD83-PE (Clone HB15), CD40-PE,
CD80-FITC, CD86-FITC, CD86-PE, CD14-PE, HLA-
DR-FITC, HLA-DR-PerCP, CD152-PE (BD Biosciences,
Franklin Lakes, NJ). Intracellular staining of CTLA4 was
as described previously [37]. The results are expressed
as the percentages of positive cells or as mean
fluorescence intensity (MFI), calculated according to the
formula: MFI = mean fluorescence (sample) - mean
fluorescence (control).
Cross-linking of CTLA4
DCs were collected, counted, and incubated in anti-
CTLA4-antibody-coated 24-well plates in complete
medium (1 × 106 cells/well) at 37°C. As controls, DCs
were incubated with an equal amount of coated-anti-
mouse-IgG2a antibody or left untreated.
Inhibition of DCs maturation
TNFa (10 ng/mL) and LPS (100 ng/mL) were added to
induce the maturation of the DCs in the wells coated
with different concentrations of anti-CTLA4 or control
antibody (anti-mouse-IgG2a). The cells were recovered
after 48-72 h of culture. CD83 expression was used as
the marker of maturity and was detected by FACs.
Endocytosis
Mannose-receptor-mediated endocytosis was measured
as the cellular uptake of FITC-Abtran (FITC-DX; Mr
40,000; Sigma) and quantified by flow cytometry.
Approximately 2 × 105 iDCs pretreated with anti-
CTLA4 antibody or the control antibody were incubated
in medium containing FITC-DX (1 mg/mL) for 0, 60, or
120 min. After incubation, the cells were washed twice
with PBS to remove excess Abtran and fixed in cold 1%
formalin. The quantitative uptake of FITC-DX by the
cells was determined with FACS. At least 10,000 cells
were analyzed per sample.
Mixed lymphocyte reaction (MLR)
DCs were cultured in GM-CSF plus IL4 for seven days,
after which maturation factors (10 ng/mL TNFa and
100 ng/mL LPS) were added for two days. The mDCs
were challenged (or stimulated) with 2 μg/mL coated-
anti-CTLA4 antibody or control antibody (anti-mouse-
IgG2a) for 24 h. The DCs were collected, irradiated
(25 Gy), washed extensively, and added in graded doses
to 2 × 105 responder cells in 96-well flat-bottomed
micro test plates (Costar, Cambridge, MA) in complete
medium containing 5% autologous plasma instead of
10% FCS. The responder cells were purified allogeneic T
cells that were depleted of APCs by passage with CD14-
and CD19-coated Dynabeads. Each group was treated in
triplicate. Thymidine incorporation was measured on
day 5 with a 16 h pulse of [3H]-thymidine (1 μCi/well,
specific activity 5 Ci/mM; Amersham Life Science,
Buckingham, UK).
Antigen (Ag) presentation assay
PPD-responsive T-cell lines were generated in our
laboratory by culturing mononuclear cells with PPD
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(50 μg/mL) for one month in the presence of IL2 (100
U/mL). The medium was changed twice a week for
medium with replenished cytokines. Peripheral mono-
cytes for DCs were obtained from the same donor as T
cells. After seven days, the DCs were preincubated with
PPD (50 μg/mL) for 12 h in serum-free RPMI 1640
medium to take up the antigen. Then medium was
replaced with medium supplemented with maturation-
inducing stimuli (10 ng/mL TNFa and 100 ng/mL LPS)
and the cells were cultured in the presence or absence
of coated-anti-CTLA4 antibody for 48 h. Isotope control
(anti-CD3) antibody was used as the antibody control.
The DCs were then washed extensively and cocultured
with a PPD-responsive autologous T-cell line for 72 h in
96-well microtiter plates. Their [3H]-thymidine uptake
was measured during the last 12 h of culture.
Statistical analysis
Results were expressed as the mean ± SD. Variance ana-
lysis was used for statistical comparisons between
groups by Student’s t-test. Statistical significance was
defined as a P value of < 0.05.
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